Cloud-Clone publishes antibody selection guide for key research methods

By AI, Created 4:57 AM UTC, June 02, 2026, /AGP/ – Cloud-Clone Corp. has released a guide aimed at helping researchers match antibodies to Western blot, IHC, IF, flow cytometry and ELISA workflows. The company says the resource is meant to reduce failed experiments, improve signal quality and speed up method selection across life sciences research.

Why it matters: - Antibody choice can make or break experiments by affecting signal quality, specificity and false-positive rates. - The guide is aimed at researchers working in Western blot, tissue imaging, flow cytometry and ELISA, where the wrong antibody can waste scarce samples and delay results. - Cloud-Clone is positioning its antibody portfolio and validation data as a way to simplify method selection and reduce trial and error.

What happened: - Cloud-Clone Corp. published an antibody selection guide focused on matching antibody traits to research applications. - The guide covers Western blot, immunohistochemistry, immunofluorescence, flow cytometry and ELISA. - The company says it offers more than 18,000 proteins, 27,000+ antibodies and 8,000+ ELISA kits in stock. - The release says Cloud-Clone has nearly 20 years of expertise in protein, antibody and ELISA detection R&D.

The details: - For Western blot, the guide says researchers should confirm the antibody is validated for WB, check band clarity and expected molecular weight, and review immunogen information. - The release says polyclonal antibodies can help with low-abundance proteins because they recognize multiple linear epitopes and can amplify signal. - The release says monoclonal antibodies are better when researchers need high specificity, clean backgrounds or distinction between splice variants and modification states. - A CD54 example in rat liver tissue is described as showing a PNGase F-treated band shifting from about 95 kDa to 58 kDa, matching the theoretical molecular weight. - The company says that result validates the antibody’s ability to recognize both glycosylated and deglycosylated CD54. - For IHC, the guide says antibodies should tolerate antigen retrieval, work with paraffin or frozen sections and produce clear DAB staining with low background. - The release says Cloud-Clone provides IHC validation images with negative controls. - For IF, the guide says researchers should use high-specificity, high-affinity antibodies that support multiplex staining without fluorescence interference. - The release cites a HepG2 multiple-immunofluorescence example using Alexa Fluor 488-labeled Tubulin Beta 1 antibody and TRITC-labeled Phalloidin. - For flow cytometry, the guide says antibodies must match live or fixed cells, the cell species and the cytometer’s detection channels. - The release says directly labeled primary antibodies are preferred for simplicity and lower background, while indirect labeling requires matched fluorescent secondary antibodies with no cross-reactivity. - Cloud-Clone says its flow cytometry antibodies are available with multiple fluorescent labels and can be customized for channel markers. - For ELISA, the guide says assay pairs must recognize different epitopes, with a high-affinity capture antibody and a high-specificity detection antibody. - The release says ELISA antibodies must be validated for cross-reactivity and compatible with sample types such as serum and cell supernatant. - Cloud-Clone says its self-developed system provides validated antibody pairs and kit products covering 8,000+ indicators. - The company also recommends multiplex assay kits for large sample sets, saying they work with Luminex and flow cytometry and can detect dozens of targets in one run.

Between the lines: - The release is both a technical guide and a product showcase. - Cloud-Clone is using application-specific validation examples to argue that antibody performance should be judged by workflow, not just by target name. - The emphasis on multi-platform compatibility suggests the company is targeting labs that want one supplier across discovery, validation and quantification workflows.

What’s next: - Cloud-Clone says it will keep investing in R&D and antibody innovation. - The company says it will continue offering technical support and full-process guidance for antibody selection and detection workflows. - Researchers can find more information at the company’s website.

The bottom line: - Cloud-Clone is pushing a simple message: matching the antibody to the assay is essential for reliable data, and the company wants its validated portfolio to be the shortcut.